Bulimia Nervosa Market: Global Market Growth by Disorder Type, Drug Class, Route of Administration, End User and Region Forecast (2023 – 2029)

Global Bulimia Nervosa Market size expected to hit USD 713.03 Mn by 2029 from USD 503.37 Mn in 2022 at a CAGR of 5.1% during the forecast period
Bulimia Nervosa Market Overview
Bulimia Nervosa is a type of eating disorder characterized by eating a large amount of food in a short period of time. The bulimia nervosa again differentiated into two types: purging and non-purging based on the eating behavior. The lack of control over eating, the secrecy surrounding eating, eating unusually large amounts of food and the Disappearance of food are some of the symptoms of Bulimia Nervosa Disorder. The increased awareness and the advancements in the diagnostic are expected to propel the growth of the Bulimia Nervosa Market. The report includes all the necessary details, which are expected to help the businesses to grow.To know about the Research Methodology :- Request Free Sample Report
Bulimia Nervosa Market Dynamics
Market Drivers

Behind the increase of bulimia nervosa eating disorder there are diverse reasons linked with each other and cause bulimia nervosa prevalence in the surrounding. The cultural shifts, westernization, technological advances and a trend of an ideal body shape and size across the world have created an eating disorder in both males and females. The report states that almost 70 million people suffer from various types of eating disorders. The above factors have increased the prevalence of bulimia nervosa, which is expected to propel the global Bulimia Nervosa Market Penetration in the major geographic regions.

The Global Impact of Westernization of Culture Expected to Boost Bulimia Nervosa Market

Most people travel to Europe and Western countries to study and to travel around the world and get influenced by Western culture and habits. This population is mostly from Asia Pacific, the region with an increased prevalence of eating disorders. Eating disorders like bulimia nervosa are not culture-bound or specific but more culture reactive.

Influence of Media Expected to Boost Bulimia Nervosa Market Penetration Globally

It is observed that body positivity and eating disorder recovery accounts become more prominent in 2020 and 2021. The growing urge in mostly young populations to establish their online presence on social media and their continuous comparison with others is expected to lead toward increased body dissatisfaction and trigger body dysmorphia, which are powerful contributing factors to the development of eating disorders. These are the major factors, which are expected to drive the Bulimia Nervosa Market. In cases where self-image is impaired and individuals compare themselves to the “beautiful people” they see on Instagram, Facebook and Twitter, social media can be a strong triggering factor in the rise of bulimia nervosa and other eating disorders. The major Bulimia Nervosa Key Companies are also using social media to spread awareness regarding the rising incidences of eating disorders across the world.

In the past several decades, the world has seen increasing industrialization and urbanization and research from 2011, by some medical journals and organizations showed that the influence of media has correlated with an increasing growth rate of the Bulimia Nervosa Industry due to feelings of negative body image and dissatisfaction in both males and females. The Bulimia Nervosa Market Penetration rate has different numbers and reasons in different cultures. The South African National Health and Nutrition Examination Survey states that females aged 10 to 14 years had a negative body image. Up to 68% and 17% of females in that age group believed they were fat, which is expected to drive the Bulimia Nervosa Market Share.

Market Restraints

The Bulimia Nervosa Market report data has been collected through primary and secondary research methods to analyze it with SWOT analysis and PORTER’s five force model. The analysis provides data regarding the factors driving the market growth, limiting the Bulimia Nervosa Market Size and new opportunities for major Bulimia Nervosa Key Companies in the top five geographic regions. The shortage of specific treatments and the availability of various therapies are expected to impede the growth of the Bulimia Nervosa Industry. Also, the people and the health personnel are not that aware of the eating disorder, which is expected to be another limiting factor for the industry.
Bulimia Nervosa Market Regional Insights
North America is expected to grow significantly throughout the forecast period in Bulimia Nervosa Market. Bulimia Nervosa is one of the types of eating disorder. The report states that global Bulimia Nervosa has increased to 7.8 percent in the past two decades. In the United States, almost half of Americans know someone with bulimia nervosa which is an eating disorder. Bulimia nervosa is very common in America among young women, which is 3.8 percent more than men, which is 1.5 percent. These factors are expected to drive North America Bulimia Nervosa Market. The region’s growth is also supported by the growing investment and research and development in Bulimia Nervosa Industry by major Bulimia Nervosa Key Players. A new trend in the region has been observed the Bulimia nervosa disorder among teens is doubled during and after the COVID-19 pandemic. This trend is concerning the health department of the country since eating disorders are among the most deadly of all mental health diagnoses, and teens with eating disorders are at higher risk for suicide than the general population. These factors are expected to drive North America Bulimia Nervosa Market.

Europe’s Bulimia Nervosa Market is expected to boost during the forecast period as per the report’s data almost 1.25 million people in the United Kingdom have an eating disorder, a collective of conditions characterized by atypical and harmful eating behaviors. According to the British eating disorder charity Beat, bulimia nervosa has the highest mortality rate of any psychiatric condition. Under the European Union regulations, many diet products are not referred to as drugs or food supplements but are considered medical devices. This allows sell of diet pills and shakes with very less marketing restrictions. These products include indigestible dietary fibers such as litramine and glucomannan, which swell up in the stomach and cause the user to feel fuller. This is expected to increase the eating disorders such as bulimia Nervosa among people and respectively drive the growth of the Bulimia Nervosa Market.

Asia Pacific is expected to emerge as the best region with lucrative opportunities for major Bulimia Nervosa Key Players in the Bulimia Nervosa Industry. The MMR research provides data regarding bulimia nervosa in the Bulimia Nervosa Market Report, which said that Japan has the highest prevalence of eating disorders in Asia Pacific followed by Hong Kong, Singapore, Taiwan and South Korea. A recently published study reported that a total of 10,542 Taiwanese have bulimia nervosa and the prevalence of bulimia nervosa in Japan is 1.03 percent in the age group of 20-24. These factors have been increasing the Bulimia Nervosa Market Share in the Asia Pacific. In summary, each of the four Asian countries discussed has seen a dramatic increase in the number of individuals diagnosed with an eating disorder. Given the growing numbers, it is important that eating disorders research continues to expand beyond the United States and Western Europe where much of the research to date has been based. Thankfully, Taiwan, Japan, South Korea, and Singapore have resources available for providers, patients, and families within their counties that promote awareness and treatment of eating disorders.
Bulimia Nervosa Market Competitive Landscape
Takeda Pharmaceutical Company Ltd, Sunovion Pharmaceuticals Inc., H. Lundbeck A/S, Orexigen Therapeutics, Inc. and Novo Nordisk A/S are some of the major Bulimia Nervosa Key Players. The report involves data regarding mergers and acquisitions, recent announcements and investments by major Bulimia Nervosa Key Companies. Recently, Takeda Pharmaceutical Co. Ltd. acquired PvP Biologics Inc. for a prenegotiated up-front payment as well as development and regulatory milestones of up to US$330 million. PvP Biologics is a San Diego-based company developing an oral enzyme for treating celiac disease and bulimia nervosa disorder. These acquisitions are expected to boost not only the medical field but the Bulimia Nervosa Market Growth. The report provides a detailed analysis of the industry through Bulimia Nervosa Competitive Benchmarking, which includes Bulimia Nervosa Market Size, Bulimia Nervosa Market Share and Bulimia Nervosa Market Revenue.
Bulimia Nervosa Market Segment Analysis
Based on Disorder Type, Non-purging is expected to have the highest prevalence in Bulimia Nervosa Market during the forecast period. People with non-purging bulimia have other behaviors or symptoms such as exercise or fasting to compensate for food consumed. These behaviors are considered excessive or extreme and can be disruptive to a person’s daily life. The trend of exercising and intermittent fasting is expected to change the eating patterns of people, which is expected to convert to Bulimia Nervosa Disorder. Both the two sub-types of bulimia nervosa have serious side effects and risks to health and possess serious long-lasting consequences. These are the factors that are expected to increase the share of the segment in the growing Bulimia Nervosa Industry. Both purging and non-purging behaviors can impact psychological, social and mental health. The thoughts and feelings are expected to hamper damage to a person’s self-health. Purging and non-purging behaviors are expected to increase the risk of chronic health conditions.

Based on the End User, The hospitals and Clinics segment held the largest revenue share in the Bulimia Nervosa Market in 2022 and is expected to dominate the market throughout the forecast period. Hospitals are the bases of the healthcare system to provide diagnostics of any disorder and cure them before reaching the severe stage. In bulimia nervosa disorder, most people are not aware that they are having an eating disorder. An eating disorder has many reasons behind it such as mental instability, psychological problem and a developed habit of intermittent fasting, which later might become a non-purging Bulimia Nervosa Disorder. Thus, the proper guidance and diagnosis of it is much needed and hospitals and clinics help impressively in this. All these factors are expected to propel the growth of the Bulimia Nervosa Market. Some of the Bulimia Nervosa Key Players have their own hospitals and clinics.
Bulimia Nervosa Market Scope: Inquire before buying



Bulimia Nervosa Market


Report Coverage
Details


Base Year:
2022
Forecast Period:
2023-2029


Historical Data:
2017 to 2022
Market Size in 2022:
US $ 503.37 Mn.


Forecast Period 2023 to 2029 CAGR:
5.1%
Market Size in 2029:
US $ 713.03 Mn.


 Segments Covered:
by Disorder Type
• Purging
• Non-purging


by Drug Class
• Antidepressant
• Anticonvulsant
• Others


by Route of Administration
• Oral
• Intravenous
• Others


by End-User
• Hospitals and Clinics
• Homecare Settings
• Specialty Centers
• Others



Bulimia Nervosa Market, by Region:
• North America (United States, Canada and Mexico)
• Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
• Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan, and Rest of APAC)
• Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
• South America (Brazil, Argentina Rest of South America)
Bulimia Nervosa Key Players include:
• Takeda Pharmaceutical Company Ltd
• Sunovion Pharmaceuticals Inc.
• H. Lundbeck A/S
• Orexigen Therapeutics, Inc.
• Novo Nordisk A/S
• Eli Lilly and Company
• Jazz Pharmaceuticals Inc.
• VIVUS Inc.
• Bausch & Lomb Incorporated
• Apotex Inc.
• Somerset Therapeutics, LLC
• Mylan N.V.
• Teva Pharmaceuticals Industries Ltd.
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Amneal Pharmaceutical LLC.
• AbbVie Inc.
• GlaxoSmithKline Plc
• Dr. Reddy’s Laboratories Ltd.
• Lupin Pharmaceuticals, Inc.
• Aurobindo Pharma
• AstraZeneca
• Bristol-Myers Squibb Company
• Johnson & Johnson Services, Inc.

Frequently Asked Questions:

1] What is the growth rate of the Bulimia Nervosa Market?
Ans. The Bulimia Nervosa Market is growing at a CAGR of 5.1% during the forecast period.

2] Which region is expected to dominate the Bulimia Nervosa Market?
Ans. North America is expected to dominate the Bulimia Nervosa Market during the forecast period from 2023 to 2029.

3] What is the expected Bulimia Nervosa Market size by 2029?
Ans. The size of the Bulimia Nervosa Market by 2029 is expected to reach USD 713.03 Mn.

4] Who are the top players in the Bulimia Nervosa Market?
Ans. The major key players in the Bulimia Nervosa Market are Takeda Pharmaceutical Company Ltd, Sunovion Pharmaceuticals Inc., H. Lundbeck A/S, Orexigen Therapeutics, Inc. and Novo Nordisk A/S.

5] Which factors contributed to the growth of the Bulimia Nervosa Market in 2022?
Ans. The Bulimia Nervosa Market is expected to grow due to the rising prevalence of eating disorders across the world.